Analysis of cranial neural crest migratory pathways in axolotl using cell markers and transplantation
Abstract
We have examined the ability of normal and heterotopically transplanted neural crest cells to migrate along cranial neural crest pathways in the axolotl using focal DiI injections and in situ hybridization with the neural crest marker, AP-2. DiI labeling demonstrates that cranial neural crest cells migrate as distinct streams along prescribed pathways to populate the maxillary and mandibular processes of the first branchial arch, the hyoid arch and gill arches 1-4, following migratory pathways similar to those observed in other vertebrates. Another neural crest marker, the transcription factor AP-2, is expressed by premigratory neural crest cells within the neural folds and migrating neural crest cells en route to and within the branchial arches. Rotations of the cranial neural folds suggest that premigratory neural crest cells are not committed to a specific branchial arch fate, but can compensate when displaced short distances from their targets by migrating to a new target arch. In contrast, when cells are displaced far from their original location, they appear unable to respond appropriately to their new milieu such that they fail to migrate or appear to migrate randomly. When trunk neural folds are grafted heterotopically into the head, trunk neural crest cells migrate in a highly disorganized fashion and fail to follow normal cranial neural crest pathways. Importantly, we find incorporation of some trunk cells into branchial arch cartilage despite the random nature of their migration. This is the first demonstration that trunk neural crest cells can form cartilage when transplanted to the head. Our results indicate that, although cranial and trunk neural crest cells have inherent differences in ability to recognize migratory pathways, trunk neural crest can differentiate into cranial cartilage when given proper instructive cues.
Additional Information
Copyright © 2000 by Company of Biologists. Accepted 3 April 2000; published on WWW 23 May 2000. This work was supported by a Howard Hughes Medical Institute Research Resources Grant and a James H. Zumberge Research and Innovation Fund (M.A.J.S.), by NS36585 and NS34671 to M.B.F. and the Deutsche Forschungsgemeinschaft (Ep8/7-1) to H.-H.E. The 12/101 monoclonal antibody, developed by Jeremy Brockes, was obtained from the Developmental Studies Hybridoma Bank maintained by The University of Iowa, Department of Biological Sciences, Iowa City, IA 52242, USA.Attached Files
Published - EPPdev00.pdf
Files
Name | Size | Download all |
---|---|---|
md5:1ef7d00c894dbcda623a3e741899528b
|
531.3 kB | Preview Download |
Additional details
- Eprint ID
- 12094
- Resolver ID
- CaltechAUTHORS:EPPdev00
- Howard Hughes Medical Institute (HHMI)
- James H. Zumberge Research and Innovation Fund
- U.S. Public Health Service (USPHS)
- NS34671
- U.S. Public Health Service (USPHS)
- NS36585
- Deutsche Forschungsgemeinschaft (DFG)
- Ep8/7-1
- Created
-
2008-10-22Created from EPrint's datestamp field
- Updated
-
2019-10-03Created from EPrint's last_modified field